The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics (NASDAQ: CAPR) announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the company’s investigational cell therapy for Duchenne muscular dystrophy (DMD). The manuscript cleared independent expert peer review, which externally validates the trial’s design, statistical methodology and findings — and it lands less than a month before Deramiocel’s PDUFA target action date of August 22, 2026.

Key Points

• HOPE-3 enrolled 106 participants in a randomized, double-blind, placebo-controlled design and met its primary endpoint.

• Deramiocel slowed upper limb function decline by 54% versus placebo on the PUL 2.0 scale (p=0.03).

• The trial also delivered clinically meaningful benefit across several cardiac measures.

• Results reflect the company’s prespecified Statistical Analysis Plan version 3.0 (SAP 3.0).

• The BLA remains under active FDA review, with a PDUFA target action date of August 22, 2026.

• The Lancet publication covers the same evidence base that will be discussed at Capricor’s upcoming Advisory Committee meeting.

A First for Non-Ambulatory Patients

Investigators framed the result as a milestone for a population that previous DMD trials have largely bypassed. “The HOPE-3 results are a landmark moment for the Duchenne community, demonstrating a significant benefit on skeletal muscle function alongside compelling data shown in cardiac function,” said Craig McDonald, M.D., Distinguished Professor of Physical Medicine & Rehabilitation and Pediatrics at UC Davis Health, National PI of the HOPE-2 and HOPE-3 trials and lead author of the publication.

McDonald went further, calling HOPE-3 the first Phase 3 trial to show a significant functional benefit in a largely non-ambulatory DMD population. Because functional decline in these patients typically progresses without reversal, a 54% slowing represents a substantial effect. Moreover, the concurrent cardiac benefits lend biological support to a consistent treatment effect spanning both skeletal and cardiac muscle.

Management Points to the Regulatory Calendar

Capricor leadership tied the publication directly to the pending FDA decision. “The totality of evidence for Deramiocel is strong, with clinically meaningful benefits now published in The Lancet, one of medicine’s most highly regarded journals,” said Linda Marbán, Ph.D., CEO of Capricor. She added that the journal’s rigorous, independent peer review further validates the results.

Marbán also emphasized that this evidence forms the foundation of the company’s BLA and will anchor the Advisory Committee discussion. Capricor has continued working with the FDA throughout the review and firmly believes the data support approval. If regulators agree, Deramiocel would become the first approved cell therapy for Duchenne.

How Deramiocel Works

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that preclinical and clinical studies have linked to potent immunomodulatory and anti-fibrotic activity. Specifically, CDCs secrete extracellular vesicles known as exosomes, which target macrophages and shift their expression profile toward a healing rather than pro-inflammatory phenotype. To date, researchers have examined CDCs in more than 250 peer-reviewed publications and administered them to over 250 human subjects across multiple clinical trials.

Regulators have granted Deramiocel a stack of designations along the way: Orphan Drug Designation for DMD from both the FDA and the European Medicines Agency, Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA — the last of which may qualify Capricor for a Priority Review Voucher upon approval.

The Unmet Need Behind the Data

DMD is a severe, X-linked genetic disorder that drives progressive degeneration of skeletal, respiratory and cardiac muscle, and it stems from the absence of functional dystrophin, a key structural protein in muscle cells. The disease affects roughly 15,000 individuals in the United States and primarily strikes boys. As the heart muscle deteriorates, patients develop cardiomyopathy and heart failure — the leading cause of death in DMD. No cure exists today, and treatment options remain limited.

Why It Matters for Investors

Consequently, the next four weeks carry outsized weight for CAPR. A top-tier journal publication strengthens the scientific record heading into both the Advisory Committee meeting and the August 22 PDUFA date, yet Deramiocel remains an investigational candidate that has not been approved for commercial use in any indication. Investors watching the small- and micro-cap biotech space should treat the regulatory outcome, not the publication, as the binary event on the calendar.